Circulating inhibitors.
Non-specific circulating inhibitors detected in 13 patients did not result in significant bleeding episodes. Five non-haemophiliacs who had inhibitors to Factor VIIIC did not have any underlying disorders but all of them experienced major bleeding episodes. Five per cent of haemophiliacs developed antibodies to Factor VIIIC. Most of them had severe haemophilia, but as the titres of antibody were low, they did not present with problems in management. Current modes of treatment for haemophiliacs with Factor VIIIC inhibitors include inducement of immune tolerance with high doses of Factor VIII, activated or non-activated prothrombin complex concentrate and plasmapheresis.